Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
Status:
Active, not recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn about how vemurafenib may affect certain
biomarkers in patients with PTC. Biomarkers are in the blood/tissue and may be related to
your reaction to the study drug. The safety of this drug will also be studied.
Vemurafenib is designed to block the BRAF gene mutation. This mutation causes cancer and
cancer growth. By blocking this mutation, the drug may kill the cancer cells with the
mutation and/or stop the tumor from growing.